Antiallergic properties of antihistamines

Allergologia et Immunopathologia

Volumn 24, Issue 4, 1996, Pages 177-183

  Negro Alvarez, J M ^a,b   Funes, E ^a   Cánovas, A García ^a   Hernandez J ^a   Garcia Selles F J ^a   Pagan J A ^a   Lopez Sanchez J D ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b NONE   (Spain)

Author keywords

antihistamine; azelastine; cetirizine; ebastine; levocabastine; loratadine; nonsedating; terfenadine

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; EBASTINE; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE; LEVOCABASTINE; LORATADINE; TERFENADINE;

ALLERGY; DRUG ACTIVITY; DRUG EFFICACY; HISTAMINE RELEASE; HUMAN; INFLAMMATION; MAST CELL; REVIEW;

BUTYROPHENONES; CELLS, CULTURED; CETIRIZINE; CLINICAL TRIALS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; HUMANS; HYPERSENSITIVITY; LEUKOCYTES; LORATADINE; MACROPHAGES; MAST CELLS; PHTHALAZINES; PIPERIDINES; TERFENADINE;

EID: 0029992622     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Davies R J., Bagnall A.C., McCabe R N., Calderon M.A. and Wang J.H. Antihistamines: topical vs oral administration. Clin Exp Allergy 1996; 26 Supl 3:11-17.
2. Kennnard C.D and Ellis C N Pharmacologic therapy for urticaria. J Am Acad Dermatol 1991, 25: 176-189.
3. Adessi B., Allegra F., Beaumont D , Bergeron D , Brunett J.L , Caperan D. et al Terfenadine once daily in chronic urticaria, a multi-centre double-blind comparison of terfenadine once daily versus twice daily Allergy 1989, 44: 447-452.
4. Shall L, Newcombe R.G. and Marks R. Assessment of the duration of action of terfenadine on histamine induced weals Br J Dermatol 1988; 119: 525-531
5. Honing P.K., Wortham D.C . Zarnani K., Conner D P., Mullin J C. and Cantinela LR. Terfenadine-ketoconazole interaction, pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 12: 1513-1518.
6. Campbell A.M , Chanez P., Marty-Ane C., Albat B., Bloom M., Michel F B. et al. Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine Allergy 1993, 48: 125-129
7. Canonica G.W, Ciprandi G., Buscaglia S., Pesce G. and Bagnasco M. Adhesion molecules of allergic inflammation recent insights into their functional roles. Allergy 1994, 49: 135-141
8. Ciprandi G., Pronzato C., Ricca V., Varese P . Del Giacco G.S. and Canonica G.W Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy Clin Exp Allergy 1995; 25: 9: 871-878.
9. Fabre J.M., Marty-Ane C , Alouzen M., Souques F., Bousquet J. and Campbell A.M. Pharmacologic heterogeneity of human and colon cells: effect of terfenadine and cetinzine. Allergy 1995; 50: 4:362-365.
10. Bousquet J., Lebel B., Chanal I., Morel A. and Michel FB. Antiallergic activity of H1 receptor antagonists assessed by nasal challange. J Allergy Clin Immunol 1988; 82: 5 (pt 1): 881-887.
11. Bagnasco M. and Canonica G W. Influence of H1-receptor antagonists on adhesion molecules and cellular traffic Allergy 1995; 50 Supl 24: 17-23.
12. Campoli-Richards DM., Buckley M M , Buckley M T and Fitton A. Cetirizine a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria Drugs 1990; 40: 5: 762-781.
13. Randazzo L, Valencia M. and Olive-Pérez A. Comparison between cetirizine and terfenadine, time response study Allergol Immunopathol 1992; 20: 119-123.
14. Sheffer A L and Samuels L.L Cetirizine: antiallergic therapy beyond traditional H1 antihistamines. J Allergy Clin Immunol 1990; 86: 6 (pt2):1040-1046
15. Fadel R., Herpin-Richard N , Rihoux J.P. and Henocq E. Inhibitory effect of cetirizine 2HCI on eosinophil migration in vivo. Clin Allergy 1987; 17: 373-379.
16. Charlesworth E.N., Kagey-Sobotka A, Norman P.S. and Lichtenstein L.M. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989; 83: 5: 905-912.
17. Michel L , De Vos C., Rihoux J.P, Burtin C , Beneviste J. and Dubertret L inhibitory effect of oral cetirizine on in vivo antigen induced histamine and PAF-acether release and eosinophil recruitment in human skin. J Allergy Clin Immunol 1988; 82: 1- 101-109
18. Fadel R.. David B , Herpin-Richard N., Borgnon A, Rassemont R. and Rihoux J.P In vivo effects of cetiricine on cutaneous reactivity and eosinophil migration induced by platelet activating factor (PAF-acether) in man. J Allergy Clin Immunol 1990; 86: 314-320.
19. Walsh G M., Moqbel R., Hartnell A and Kay A.B. Effects of cetirizine on human eosinophil and neutrophil activation in vitro. Int Arch Allergy Appl Immunol 1991; 95: 158-162.
20. Leprovost C , Capron M , De Vos C., Tomassini M. and Capron A Inhibition of eosinophil chemotaxis by a new antiallergic cornpound, cetirizine. Int Arch Allergy Appl Immunol 1988; 87: 9-13.
21. De Vos C , Joseph M., Leprovost C., Vorng H., Tomassini M., Capron M et al. Inhibition of human eosinophil chemotaxis and of IgE-dependent stimulation of human blood platelets by cetirizine. Int Arch Allergy Appl Immunol 1989; 88: 212-215
22. Sehmi R , Walsh G.M , Hartnell A, Barkans J., North J., Kay A B. et al Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro Pediatr Allergy Immunol 1993; 4Supl 4- 13-18
23. Cheria-Samman S.. Aloui R , Gormand F., Chabannes B., Gallet H , Grosclaude M. et al. Leukotriene B4 production by blood neutrophils in allergic rhinitis -effects of cetirizine Clin Exp Allergy 1995; 25: 8: 729-736.
24. Caproni M., Palleschi G M., Falcos D., Papi C and Lotti T. Pharmacologic modulation by cetirizine of some adhesion molecules expression in psoriatic skin lesions Int J Dermatol 1995; 34-7: 510-513.
25. Ciprandi G , Buscaglia S., Pesce G , Passalacqua G., Rihoux J.P. and Bagnasco M. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen- specific challenge. J Allergy Clin Immunol 1995; 95: 2: 612-621.
26. Clissold S.P., Sorki E.M. and Goa K.L. Loratadine A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989; 37: 42-57
27. Negro Alvarez J.M Aspectos terapeúticos actuates de la rinitis alérgica estacional. Inflamación 1996, 7: 3: 182-198
28. Kreutner W, Chapman R.W, Gulbenkian A. and Siegel M.I. Antiallergic activity of loratadine, a non-sedating antihistamine Allergy 1987; 42: 57-63.
29. Emery D.L., Siegel M.I., Cuss F.M., Danzig M.R., Fish J.E. and Peters S.P. Loratadine inhibits mediator release from dispersed human lung mast cells. Clin Exp Allergy 1990; 20: 40
30. Marone G , Patella V , Casolaro E., Marchesi E. and Bianchi B. Inhibition of mediator release from human mast cells by loratadine J Allergy Clin Immunol 1994; 93 (pt 2): 258.
31. Miadonna A., Milazzo N., Lorint M., Marchest E. and Tedeschi A Inhibitory effect of the HI antagonist loratadine on histamine release from human basophils. Int Arch Allergy Immunol 1994; 105: 12-17.
32. Miadonna A, Milazzo N , Lonni M , Marchesi E. and Tedeschi A. Antiallergic activity of loratadine. inhibition of leukotnene C4 release from human leucocytes. Clin Exp Allergy 1995; 25: 4: 364-370.
33. Temple D M and McCluskey M Loratadine, an antihistamine, block antigen and Ionophore induced leukotnene release from human lung in vitro. Prostaglandins 1988; 35: 549-554
34. Ramachers U., Amon U. and Wolff H.H. Direct effects of second-generation H1 -receptor antagonist on the activation of human basophils Agent Action 1994; 41 : C-45-C-46
35. Berthon B., Taudou G , Combettes Let al In-vitro inhibition by Ioratadine and descarboxyethoxyloratadine, of histamine release from human basophils and of histamine release and intracellular calcium flux's in rat basophilic leukaemia cells Biochem Pharmacol 1994; 47: 789-794.
36. Vignola A M , Crampetre L., Mondain M , Sauvere G., Czarlewski W , Bousquet J. et al. Inhibitory activity of loratadine and descarboethoxy-loratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells Allergy 1995; 50: 3: 200-203.
37. Molet S., Gossett P., Czarlewski W. and Tonnel A.B. Inhibition by loratadine of histamine-induced activation of human endothelial cells. Am J Respir Crit Care Med 1995; 151: A380
38. Czarlewski W., Chanal I., Michel F.B. and Bousquet J Evaluation of loratadine on conjunctival provocation test with orchard grass pollen extracts. J Allergy Clin Immunol 1993.91 1 (pt 2). 197.
39. Staquet M.J., Reano A., Schmitt D and Czarlewski W. Loratadine downregulates ICM-1 induced expression on normal human epidermal cells. J Allergy Clin Immunol 1995; 1 (pt 2): 299.
40. Lippert U., Kruger-Krasagakes S and Möller A. Loratadine and dexamethasone potently suppress secretion of IL-6 and IL-8 by human mast cell and basophilic cells Proc XV Int Con Allergol Clin Immunol 1994; Supl 2: 22
41. Amsellen C., Czarlewski W., Lagarde M , Perrin Fayolle M. and Pacheco Y. Effect of loratadine on leukotriene B4 level in simulated blood neutrophils from healthy and allergic subjects. Allergy 1995; 50 Supl 26: 77-78.
42. Fabrigoule M., Kaplanski G , Vasseur F., Farmer C. and Borgrand P. Loratadine inhibits histamine-induced enhancement of Pselection expression by human umbilical vein endothelial cells. Allergy 1995; 50 Supl 26: 200.
43. Eda R., Sugiyama H , Hopp R J., Bewtra A K. and Townley RG Effect of loratadine on human eosinophil function in vitro. Ann Allergy 1993, 71: 373-378.
44. Paubert-Braquet M. and Czarlewski W. Effect of loratadine and SCH34117 on Superoxide anion production from human polymorphonuclear neutrophils and monocytes J Allergy Clin Immunol 1994; 93: 257.
45. Ciprandi G., Buscaglia S, Pesce G P., Marchesi E. and Canonica G.W Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96: 344-347.
46. Ciprandi G., Buscaglia S., Marchesi E., Danzig M , Cuss F and Canonica G W Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Appl Immunol 1993; 100: 185-189.
47. Andersen M., Nolte H , Baumgarten C. and Pipkorn U. Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy 1991; 46: 540-546.
48. Greiff L , Persson C G , Svensson C , Enander I. and Andersson M. Loratadine reduces allergen-induced mucosal output of a2 -macroglobulin and tryptase in allergic rhinitis. J Allergy Clin Immunol 1995; 96: 1:97-103.
49. Raptopoulou-Gigi M., llonidis G., Orphanou-Koumerkeridou H., et al. The effect of loratadine on activated cells on the nasal mucosa in patients with allergic rhinitis. Invest Allergol Clin immunol 1993; 3: 192-197.
50. Michel L., Czarlewski W., Lemque P.. Jean-Louis F , Cougnard J. and Dubertret L. Pilot study of efficacy of loratadine on cuta- neous allergic reactions using skin chamber technique. Clin Exp Allergy 1992; 22: 137.
51. Hanna K.M and Riad AY Immunological evaluation of loratadine in patients with nasal allergy Ann Allergy 1994; 72: 84.
52. Davies R J., Lund V.J. and Harten-Ash V.J. The effect on intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis Rhinology 1993; 31:159-164
53. Shin M.H., Baroody F., Proud D., Kagey-Sobotka A., Lichtenstein L M. and Nacleiro R M. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992; 22: 289-295.
54. Grossman J., Halverson P C., Mctzlcr E O., Shoenwetter W.F., Van Bavel J.H , Woehler T.R et al. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. Ann Allergy 1994; 73: 141-146.
55. Little M.M. and Casale T.B. Azelastine inhibits IgE mediated human basophil histamine release. J Allergy Clin Immunol 1989; 83: 862-865.
56. Pronzato C., Ricca V., Varese P., Truffelli T, Bertolini C., Ciprandi G. et al. Evaluation of antiallergic activity of azelastine nasal spray. Allergy 1995; 50 Supl 26: 69.
57. Buscaglia S., Catrullo A., Fiorino N., Pesce G.P., Montagna G., Ciprandi G.W. et al Azelastine eye drops exerts antiallergic activity. Allergy 1996; 51 Supl 31: 43.
58. Kanai H , Nagashima A., Hirakata E., Hirakata H , Okuda S., Fujimi S et al The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients. Life Sci 1995; 57: 3:207-213.
59. Dechant K.L. and Goa K.L. Levocabastine a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41: 2: 202-224.
60. Arriaga F and Rombaut N. Absence of central effects with levocabastine eye drops. Allergy 1990, 45: 552-554
61. Jannssens M.M.L. Levocabastine a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis. Rhinology 1932; 13 Supl: 39-49.
62. Pazdrak K., Gorski P and Ruta U. Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx Allergy 1993; 48: 598-601.
63. Van Wauwe J P. Animal pharmacology of levocabastine: a new type of H1-antihistamine well suited for topical application. In. Mygind N, Naclerio RM, eds. Rhinoconjunctivitis: new perspectives in topical treatment Toronto. Hogrefe & Huber, 1989. 27-34
64. Buscaglia S , Catrullo A, Ciprandi G , Presce G.P , Fiorino N., Paoleri F. et al Levocabastine eye drops reduces ICAM-1 expression both in-vitro and in vivo. Allergy 1995; 50 Supl 26: 79.
65. Roberts D.J. A preclinical overview of ebastine: studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Drugs 1996; 52 Supl 1; 8-14.
66. Torrent J., Barbanoj M.F. and Izquierdo I Ebastine pharmacokinetics and antihistamine effect in man [abstractl. HER Allergy Prod 1988; 9-474.
67. Vincent J., Liminana R., Meredith P.A. and Reid J.L. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects Br J Clin Pharmacol 1988, 26: 497-502
68. Campbell A., Michel F B , Bremard-Oury C., Crampette L and Bousquet J. Overview of allergic mechanisms: ebastine has more than an antihistamine effect. Drugs 1996; 52 Supl 1, 15-19.